A. E. Eskazan, "Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase," EXPERT OPINION ON PHARMACOTHERAPY , vol.18, no.3, pp.325-326, 2017
Eskazan, A. E. 2017. Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. EXPERT OPINION ON PHARMACOTHERAPY , vol.18, no.3 , 325-326.
Eskazan, A. E., (2017). Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. EXPERT OPINION ON PHARMACOTHERAPY , vol.18, no.3, 325-326.
Eskazan, Ahmet. "Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase," EXPERT OPINION ON PHARMACOTHERAPY , vol.18, no.3, 325-326, 2017
Eskazan, Ahmet E. . "Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase." EXPERT OPINION ON PHARMACOTHERAPY , vol.18, no.3, pp.325-326, 2017
Eskazan, A. E. (2017) . "Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase." EXPERT OPINION ON PHARMACOTHERAPY , vol.18, no.3, pp.325-326.
@article{article, author={Ahmet Emre EŞKAZAN}, title={Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase}, journal={EXPERT OPINION ON PHARMACOTHERAPY}, year=2017, pages={325-326} }